Eledon Pharmaceuticals Inc
$ 1.59
0.00%
04 Dec - close price
- Market Cap 119,304,000 USD
- Current Price $ 1.59
- High / Low $ 1.67 / 1.57
- Stock P/E N/A
- Book Value 1.52
- EPS -1.30
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -0.95 %
- 52 Week High 5.08
- 52 Week Low 1.35
About
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, focused on developing innovative therapies for patients suffering from autoimmune diseases and amyotrophic lateral sclerosis (ALS), with a particular emphasis on those requiring organ or cell transplantation. The company is advancing its proprietary drug candidates through rigorous clinical trials aimed at addressing substantial unmet medical needs within these patient demographics. With a strong pipeline and a strategic commitment to improving transplant outcomes, Eledon is well-positioned to make a significant contribution to the biopharmaceutical sector and improve the lives of patients facing these challenging health conditions.
Analyst Target Price
$8.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-19 | 2024-06-20 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.21 | -0.13 | -0.08 | -0.9456 | -0.32 | -1.06 | -0.34 | -0.29 | -0.35 | -0.4 | -0.75 | -0.69 |
| Estimated EPS | -0.2414 | -0.22 | -0.3033 | -0.3267 | -0.31 | -0.3 | -0.37 | -0.39 | -0.46 | -0.46 | -0.6 | -0.7 |
| Surprise | 0.0314 | 0.09 | 0.2233 | -0.6189 | -0.01 | -0.76 | 0.03 | 0.1 | 0.11 | 0.06 | -0.15 | 0.01 |
| Surprise Percentage | 13.0075% | 40.9091% | 73.6235% | -189.4399% | -3.2258% | -253.3333% | 8.1081% | 25.641% | 23.913% | 13.0435% | -25% | 1.4286% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2371 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELDN
2025-10-18 08:47:32
This article indicates that Eledon will present results related to its kidney transplant rejection drug at an upcoming ASN meeting. However, due to an application error, the content of the article is unavailable. The page displays an error message instead of the expected news content.
2025-10-18 00:22:15
This article announces that Eledon will present results for its kidney transplant rejection drug at the upcoming ASN meeting. However, due to an application error on the website, the actual content of the announcement is not available. The rendered content only shows an error message instead of the expected news article.
2025-10-17 22:39:17
This article indicates that Eledon is scheduled to present results for its kidney transplant rejection drug at an upcoming ASN meeting. However, due to a client-side error, the actual content detailing these results or the presentation information is not displayed. Therefore, specific details about the drug and its performance remain unknown in this instance.
2025-10-17 11:57:21
This article indicates an application error preventing the content from loading. Therefore, no information about Eledon's kidney transplant rejection drug results or presentation at the ASN meeting is available.
2025-10-17 11:48:46
This article indicates that Eledon is scheduled to present results concerning a kidney transplant rejection drug at an upcoming ASN meeting. However, due to a client-side exception, the actual content of the announcement is unavailable. The page displays an error message instead of the expected news article.
2025-10-17 11:11:00
Eledon Pharmaceuticals announced it will present topline results from its Phase 2 BESTOW trial for tegoprubart at Kidney Week 2025, focusing on preventing rejection in kidney transplantation. Dr. Andrew Adams will present the findings on November 6, 2025, followed by a company conference call on November 7. Tegoprubart targets CD40 Ligand and is being developed for various immune-modulating therapies.
